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The interaction between T cell receptors (TCR) and peptide-major histocompatibility
complex (pMHC) antigens can lead to varying degrees of agonism (Tcell activation), or
antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-
derivedpeptide,gp33residues 33–41(KAVYNFATC),presented inthe contextof H-2D
b.
The cellular responses to various related H-2D
b peptide ligands are very well
characterised, and P14 TCR-transgenic mice have been used extensively in models of
virusinfection,autoimmunityandtumourrejection.Here,weanalysethebindingof the
P14 soluble TCR to a broad panel of related H-2D
b-peptide complexes by surface
plasmon resonance, and compare this with their diverse cellular responses. P14 TCR
binds H-2D
b-gp33 with a KD of 3 lM( 0.5 lM), typical of an immunodominant
antiviralTCR, butwithunusuallyfastkinetics(koff =1s
–1),correspondingtoahalf-life
of 0.7 s at 25
C, outside the range previously observed for murine agonist TCR/pMHC
interactions. The most striking feature of these data is that averyshort half-life does not
preclude the ability of a TCR/pMHC interaction to induce antiviral immunity,
autoimmune disease and tumour rejection.
Introduction
The interaction between a T cell receptor (TCR) and an
MHC-peptide complex (pMHC) underpins the biological
nature of any given Tcell response [1]. This interaction
impinges upon the development of Tcells in the thymus,
thereby shaping the repertoire of T cells entering the
peripheral pool. Relatively high affinity/avidity inter-
actions (affinity being a measurable biophysical para-
meter,aviditybeingamorelooselyusedtermtodescribe
multivalent interactions between cells) with self pMHC
in the thymus result in death of immature double-
positive T cells, a process known as negative selection
[2], whereas low affinity/avidity interactions result in
survival and differentiation of immature thymocytes
into single-positive mature T cells which enter the
periphery, a process known as positive selection.
Although high-affinity interactions between TCR and
pMHC complexes cause death of thymocytes, similar
interactions result in activation of mature T cells in the
periphery. On the other hand, positively selecting
ligands do not activate mature T cells, although low-
affinity interactions between mature T cells and self
pMHC complexes are essential for the maintenance of
the peripheral T cell pool [3].
In the periphery, the type of response elicited in a
given T cell by different pMHC complexes is varied.
Within the CD8
+ T cell population, some peptides,
known as strong agonists, are potent inducers of T cell
activation. Such peptides are efficient at inducing TCR
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effector function (including cytotoxic activity) in
response to a range of peptide concentrations. Weak
agonist peptides induce TCR down-regulation, T cell
proliferation and effector function inefficiently and only
in response to high peptide concentrations, whilst
partial agonists may stimulate some TCR down-regula-
tion and proliferation but fail to induce effector function
[4]. Some weak or partial agonists also demonstrate
antagonist activity characterised by in vitro inhibition of
lysis of target cells pulsed with agonist peptides.
Manystudies have focused on identifying factors that
determine the result of an encounter between a given
TCR and various pMHC complexes. It is accepted that
TCR bind MHC peptide complexes with very low affinity
(1–50 lM) and rapid on-off kinetics at 25
C (seconds).
Several groups have reported that strong agonists
display higher affinities and slower dissociation rates
than weaker agonists and antagonists. These data
support a kinetic proofreading model where the
principle binding parameter controlling Tcell activation
is the TCR off-rate or mean dwell-time. Stronger TCR/
pMHC interactions generally give better Tcell responses
[5]. There are exceptions, however, and antagonist
peptides from some studies have been shown to exhibit
slowerTCRdissociationratesthanagonistpeptidesfrom
other studies [6]. It is also possible that multiple TCR
could interact sequentially with pMHC molecules (serial
triggering model), thereby increasing T cell sensitivity
[7]. In this model, the TCR has an optimal mean dwell-
time beyond which T cell sensitivity is not increased
because optimal signalling occurs by multiple TCR
interacting in series with limiting specific pMHC. More
recent data implies that discrepancies such as those
described above can be accounted for by changes in
conformational heat capacity (DCpconf), a parameter
that reflects the change in the conformation of the TCR
and that, as well as half-life, contributes to the
stimulatory potential of the TCR/pMHC interaction
[8]. DCpconf cannot be measured directly unless
structures of bound and unbound TCR are available,
but DCp (the total heat capacity change for the binding
reaction) can be measured from a plot of DG
 (the free
energy change for the binding reaction) against
temperature, and this provides a limit for DCpconf.
The P14 TCR is specific for the H–2D
b-gp33 peptide
(KAVYNFATC) derived from lymphocytic choriomenin-
gitis virus (LCMV). P14 TCR-transgenic mice have been
extensively used for analysing T cell responses to the
index peptide, gp33, and a range of altered peptide
ligands (APL), including antagonists and strong, weak
and partial agonists previously shown to elicit a wide
range of biological effects [9]. The usefulness of
studying the P14 TCR derives from the fact that
Tcells bearing this particular TCR have been extensively
studied in murine models of autoimmunity, antiviral
immunity and tumour rejection [4, 10–12]. Indeed,
recognition of the index peptide by the P14 TCR can
result in autoimmunity, antiviral immunity and tumour
rejection while only some, if any, of these effects are
mediated by the variant peptides. In addition, some of
the peptide variants have been shown to induce positive
and/or negative selection of P14 in fetal thymic organ
cultures. The use of surface plasmon resonance (SPR) to
measure off-rates and affinities for the P14 TCR and a
range of related and well-characterised pMHC com-
plexes offers a unique opportunity to examine the
influence of off-rate and affinity on the biological
consequences of T cell activation.
Results and discussion
T cell activation induced by related peptide
ligands
Related peptide ligands derived from LCMV were tested
for their ability to activate P14 transgenic T cells. T cell
activation was measured by TCR down-regulation and
by measuring the peptide concentration required for
half-maximal proliferation (Table 1). Also, because of
the likely influence of pMHC stability on T cell
activation, we measured the stability of peptide binding
by H-2D
b using an RMA-S stabilisation assay (Table 1).
This group of peptides was chosen because their
biological characteristics have been extensively docu-
mented previously [4, 10–14]. As shown in Table 1, the
group includes strong agonists, weak and partial
agonists and peptides that exhibit antagonist activity.
Those peptides best at inducing TCR down-regulation
are the strong agonists while antagonists are the least
efficient at inducing TCR down-regulation. The next set
of experiments was performed to determine whether
binding of P14 to the different pMHC complexes
correlated with T cell activation potency.
Binding of P14 TCR to H-2D
b-gp33
In order to examine the binding of TCR to pMHC by
Biacore SPR, it is necessary to construct artificially
modified TCR that are stable in the soluble state. In
order to achieve this, we expressed the extracellular
domains and introduced a non-native disulphide bond.
This strategy has previously been used to produce
several heterodimeric TCR and does not result in any
significant difference in affinity [15] or structure [16]
compared with the same TCR produced by alternative,
more established constructs. The kinetics of binding are
also not affected by this non-native disulphide bond (D.
Cole, unpublished data).
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peptide, gp33, using a Biacore 3000 SPR instrument at
25
C (Fig.1). We observed small amounts of irreversible
non-specific binding even when conducting binding
experiments immediately after gel filtration chromato-
graphy of the P14 TCR. This binding is likely due to very
small quantities of denatured TCR aggregates. We
observed preferential binding to the first flow cell
regardless of the orientation of the test and control flow
cells (data not shown), confirming the non-specific
nature of aggregate binding. This artefact also becomes
more apparent at high analyte concentrations
(>5  KD), and at higher temperatures (probably due
to the increased strength of hydrophobic interactions),
making these data more difficult to analyse. We
performed sequential injections with high TCR concen-
trations and did not observe any reduction in the
binding response, indicating that this non-specific
irreversible binding component does not interfere with
specific TCR binding in these experiments.
The P14 TCR binds to its cognate ligand with
extremely rapid kinetics, but with an equilibrium
affinity within the range previously observed for other
antiviral TCR (3  0.5 lM; Fig. 1B, Table 2). In
particular, the off-rate (measured at 25
C) of approxi-
mately 0.975 s
–1 corresponds to a half-life (t1/2)o f
0.71 s–approximately2–35times faster thanpreviously
observed for other agonist ligands (reviewed in [17]).
Due to the very fast kinetics of binding, it was not
possible to reliably measure P14 TCR on-rates, even at
lower temperatures. We also measured P14 TCR binding
at various temperatures, summarised in Table 2, and
plotted the calculated DG
 values against temperature to
obtain values of DH
 (the change in enthalpy)
= –10.8 kcal/mol, DS
 (the change in entropy)
= –8 cal/mol and DCp (the change in heat capacity)
= –0.6 kcal/mol. Since DCpconf cannot exceed the value
of DCp (because this would require the binding surface
area to be negative), the maximum possible value of
DCpconf is –0.6 kcal/mol. This DCp value is similar to
previously reported TCR/pMHC interactions [8].
2.3 P14 TCR binding to altered peptide ligands
In order to ensure that there was direct comparability
between the measurements for various APL, we
measured all of the APL binding data with a single
preparation of P14 TCR. Fig. 2 shows the equilibrium
binding curves for P14 TCR binding to various altered
peptide ligands summarised in Table 1. Owing to the
extremely fast kinetics, it was not possible to measure
kinetic parameters for most of the APL, but in the few
instances where off-rates could be estimated, they
correlated with equilibrium dissociation constant mea-
surements. It is likely that, with the extremely rapid on-
rate we observed, this parameter is diffusion limited and
changes in off-rate are therefore directly reflected by
changes in KD values. Many of the APL bind H-2D
b with
very similar affinity to the wild-type peptide, and for
these peptides, the binding affinities correlate with their
T cell activation potency. For all other peptides, the
relationship between their Tcell activation potency and
TCR binding affinity is accounted for by the stability of
the pMHC complex; e.g. A3V is a relatively weak agonist
due to the poor stability of the pMHC complex (<1 h),
whereas M9C is a potent agonist due to its much higher
affinity for H-2D
b [18] causing a greater stability of
its pMHC complex (>1 h). Most unstable complexes
(t1/2 <1 h) contained amino acid substitutions at
position 5, previously identified as an anchor residue
for D
b, although clearly there are exceptions since the
lower affinity and reduced stability exhibited by peptide
A3V are accounted for by the change at position 3.
Overall, however, binding affinity of the TCR/pMHC
complexes was found to correlate well with T cell
activation potency (r = 0.63; Fig. 3). Indeed, TCR
binding affinity and pMHC stability adequately account
fortheobservedTcellactivationpotenciesinthissystem.
Thermodynamic measurements
We also measured changes in enthalpy (DH
), entropy
(DS
) over the temperature range of 4–37
C and thus
calculated the change in total heat capacity (DCp). We
have measured the affinity of the P14 TCR to various
altered peptide ligands and find that the affinity of the
TCR for each pMHC correlates well with the biological
response to each of these peptides (Fig. 3). This study
focused on the P14 TCR since previous in vivo studies
haveamplydemonstratedtheagonisticpropertiesof this
interaction in that recognition of H-2D
b/gp33 by P14
transgenic T cells results in a wide range of biological
Table 2. Binding parameters for P14 soluble TCR to H-2D
b-gp33
Temperature (
C) Equilibrium KD (lM) Off-rate, koff (s
–1) Half-life (s)
4 1.55 0.221 3.1
25 2.42 0.975 0.71
37 6.48 n.d. n.d.
n.d. = not determined
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[4] and antiviral immunity [19].
Our measurementof DH
 of –10.8 kcal/mol is similar
to measurements made in other systems (e.g. –13 kcal/
mol for 2B4 binding to MCC [8]), whereas our DS

measurement of –8 cal/mol is significantly smaller than
the measurements of –20 cal/mol for 2B4 TCR binding
to MCC [8] and –51 cal/mol for the JM22 TCR binding
to HLA-A2-flu [20]. This implies that the amount of
bond formation is similar, but the degree of ordering
requiredissignificantlylower for theP14TCRbindingto
H-2D
b-gp33. The relatively low DS
 for P14 binding
could therefore be responsible for the fast kinetics inthis
system. This is likely to be caused by relatively small
amounts of molecular rearrangement upon P14 TCR
binding, i.e. neither the TCR nor the pMHC need to
significantly change their structures to enable successful
binding, and water is also not significantly restructured,
unlike in the LC13 TCR–B8-EBV system where DS

= +11.5 cal/mol at least partially due to the release of
structured water during binding [21].
To account for anomalies in the correlation between
off-rates and Tcell activation potency, ~Cpconf has been
proposed as aparameter that contributes to determining
Figure 1. (A) Binding of P14 soluble TCR to H-2D
b-gp33 peptide measured by SPR. Background responses to the control flow cell
were subtracted and all data were plotted with the injection point at 0 s. (B) Equilibrium binding of soluble P14 TCR to H-2D
b-gp33
peptide. (C) Arrhenius analysis of dissociation kinetics for the P14 TCR binding to H-2D
b-gp33; Arrhenius dissociation energy.
~Ea
diss = 13 kcal/mol. (D) SPR binding of soluble P14 TCR binding to H-2D
b-gp33 at various temperatures. (E) Plot of ~G against
temperature alongwithaleast-squaresfitoftheequation~G

T= ~H
 + ~CP(T – T0)–T~S
 – T~CPln(T/T0) toprovideanestimate
of ~Cp.
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f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euFigure 2. Equilibrium binding of P14 soluble TCR to H-2D
b complexed with various altered peptide ligands measured by Biacore
3000 SPR at 25
C. Peptide abbreviations as in Table 1.
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evidence for this in the case of the P14 TCR, which
displays a typical ~Cp of –0.6 kcal/mol (Fig. 1E), and
~Cpconf cannot exceed ~Cp since this would require a
negative interaction surface. A typical ~Cp value
excluding ~Cpconf, calculated from various TCR/pMHC
structures, is –0.25 kcal/mol [21], implying that
~Cpconf for the P14 TCR binding is likely to be
approximately –0.35 kcal/mol.
Discussion of activation models
Based on systems described in the literature, our finding
that the P14 TCR/MHC-gp33 interaction has a half-life
of only 0.7 s is unexpected. The brevity of this
interaction places it well below the spectrum of off-
rates that have previously been observed for agonist
ligands (comprehensively reviewed in [23]). Indeed,
TCR/pMHC mean dwell-times of <1 s have previously
only been described for antagonist ligands. Thus, the
P14/MHC-gp33 interaction extends the range of inter-
actions that can result in T cell activation.
The kinetic proofreading model of T cell activation
postulates that the off-rates of TCR/pMHC interactions
correlate with their activation potencies. It is likely that
the differences in affinity we observe between APL in
the P14 system (Table 1) are the result of differences in
the off-rate of the interaction. Thus, the order of
potency within the ligands for the P14 TCR conforms to
that predicted by kinetic proofreading. The difficulty
comes when the P14 system is compared to other
systems where ligands with half-lives of <1 s act as
antagonists or have no biological activity. While our
data do not directly challenge the concept of kinetic
proofreading, they do show that it is impossible to
define an absolute TCR/pMHC off-rate at 25
C for Tcell
activation across all systems. Thus, our findings suggest
that, at a minimum, the concept of kinetic proofreading
requires further refinement to account for the >10-fold
difference between agonist TCR/pMHC off-rates in
different systems. We are unable to determine what
other factors might account for these differences from
our study of the interaction of soluble molecules in
three dimensions by SPR. However, it is very likely that
the outcome of antigen engagement at the cell surface
will depend on the particular context of the TCR that is
being engaged.
There are several ways that this context could vary
between Tcells with different TCR, which might explain
why the TCR/pMHC off-rates measured by SPR for a
particular TCR from one Tcell might not bear any direct
relationship to the off-rates measured by SPR for
another system. Firstly, the temperature at which
Biacore SPRis performed is25
C (the'standard' physical
temperature), whereas the temperature of T cell activa-
tion assays is 37
C. However, it seems unlikely that
TCR/pMHC interactions would disproportionately vary
between these temperatures between different systems.
Indeed, all TCR/pMHC interactions seem to increase in
their rapidity at 37
C compared to 25
C (Fig. 1D), and
by similar extents (D. Cole, unpublished data). Sec-
ondly, Schamel et al. [24] have recently discovered that
the TCR on a given Tcell can vary in their multivalency.
This could occur systematically between different Tcells
with different TCR, leading to varying levels of
sensitivity between the different T cells. The avidity
effect of multivalent TCR may enable some T cells to
compensate and activate in response to weaker or
shorter interactions than others. Thirdly, the level of
preformed TCR/coreceptor complexes on the T cell
surface, thought to be better at responding to antigen
than uncomplexed TCR, may vary [25]. Thus, both the
level of multivalent aggregates and the level of
TCR/coreceptor complexes can differ between T cells,
and could explain why the off-rates of two ligands that
arepotentactivatorsofdifferentTcellsmeasuredbySPR
might bear no obvious relationship. Fourthly, it is
possible that TCR/pMHC interactions may be differen-
tially affected by the mechanical stress induced byTcell-
APC interaction [23]. Finally, it is likely that the pMHC
concentrations on the surface of APC vary between
different T cell specificities. We have measured the
stability of the various peptides in the H-2D
b MHC
molecule (Table 1), but it is also likely that variations in
peptide processing efficiency may influence this para-
meter to a significant degree. Very few peptide antigens
have been accurately measured for their level of cell
surface expression, but the range of reported peptide
antigen levels is from *300 copies/cell down to
*8 copies/cell[26].ItispossiblethatTcells responding
Figure 3. Binding affinities of P14 and the various APL were
plotted against % TCR down-regulation observed upon stimu-
lation with each peptide at 10
–6 M concentration. The correla-
tion coefficient was calculated as 0.63, using Excel software
(p <0.01).
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than those responding to scarcer peptides.
Concluding remarks
In conclusion, we report that binding of the P14 T cell
receptor to its cognate ligand occurs with the fastest
kinetics reported for an agonist TCR to date, yet all other
thermodynamic parameters are within the range pre-
viously observed for TCR/pMHC interactions. This
observation significantly broadens the range of off-rates
that have been observed for TCR binding to immunodo-
minant agonist peptides. Although the data for P14 TCR
binding to altered peptide ligands do not contradict the
kinetic proofreading model of T cell activation, they
certainly show that it is difficult to define a single
parameterthatgovernsTcellactivationforallTcells.More
questions will be answered by studying engineered TCR
withdefinedpropertiesproducedbytherecentlyreported
TCRphagedisplaytechnology[27],e.g.TCRwithfasteror
slower kinetics but with similar equilibrium KD.
Materials and methods
TCR down-regulation
Spleen cells from transgenic mice were mixed with peptide-
pulsed macrophages, centrifuged and incubated at 37
Ci n
IMDM supplemented with 10% FCS in round-bottom 96-well
plates. Macrophages were pulsed with the different peptides
(10
–6 M) for 1 h at 37
C and subsequently washed twice. After
4 h, the cells were harvested and stained with CD8- and Va2-
specific antibodies before analysis by flow cytometry.
Binding assays
MHC class I stability assays were performed using the TAP-
deficient cell line RMA-S [28]. RMA-S cells were washed once
in PBS and cultured in serum-free RPMI containing 100 lM
peptide. After a 2-h incubation at 37
C, the cells were washed
three times in cold RPMI. The cells were resuspended in 1 mL
serum-free RPMI and incubated for 0, 30, 60 and 90 min at
37
C. Aliquots of 2  10
5 cells were removed at each time
point for staining with a FITC-conjugated conformation-
dependent H-2D
b-specific antibody (Pharmingen). Subse-
quently, the cells were resuspended and fixed in PBS
containing 0.5% paraformaldehyde and analysed by flow
cytometry using CellQuest software. The half-life of the MHC-
peptide complexes was measured by calculating the fluores-
cence index (FI) at each time-point. FI = (mean fluorescence
sample – mean fluorescence background)/(mean fluorescence
no peptide – mean fluorescence background).
Expression of P14 soluble TCR
TCRa and b cDNA was a generous gift from Prof. Hans-Peter
Pircher (Freiburg, Germany). Overlapping PCR was used to
introduce the following mutations (IMGT numbering/nomen-
clature: http://imgt.cines.fr): TRAC01 threonine 49 ? cy-
steine, TRBC01 serine 56 ? cysteine, TRBC01 cysteine 70 ?
serine [15]. This introduces an inter-chain disulphide bond in
the folded protein while removing the free cysteine in the
b chain. TCR a and b chains were truncated immediately prior
to the membrane-proximal cysteines and were cloned into the
pGMT7 expression vector to produce pJMB098 and pJMB099,
respectively [15].
Modified TCR a and b chains were expressed separately as
insoluble inclusion bodies in E. coli strain BL21-DE3 (Nova-
gen). Inclusion bodies were washed several times, then
denatured in 6 M guanidine-HCl, 10 mM DTT, 2 mM EDTA,
50 mM Tris pH 8.1, and quantified using a Coomassie binding
assay (PerBio). Using 30 mg of each TCR chain, refolding was
performed by rapid dilution into 1 L of 5 M urea, 0.4 M
L-arginine-HCl, 0.1 M Tris pH 8.1, 2 mM EDTA, 6.5 mM
cysteamine, 3.5 mM cystamine. Following overnight incuba-
tion at4
C, the mixture was dialysedtwice againsttenvolumes
of 10 mM Tris pH 8.1. Refolded soluble TCR was then purified
by anion exchange chromatography on a 5-mL QFF column
(Amersham). Soluble P14 TCR eluted first at approximately
150 mM NaCl and was concentrated to approximately 1 mL by
centrifugal concentration (Amicon centriprep) prior to size-
exclusion chromatography on a Superdex 200 HR column
(Amersham) equilibrated in 10 mM Hepes pH 7.4, 150 mM
NaCl, 3 mM EDTA, 0.01% P-20. P14 soluble TCR eluted at
approximately 15.5 mL and was concentrated to approxi-
mately 5 mg/mL by centrifugal concentration (Amicon
centricon). TCR concentration was measured by spectro-
photometry at 280 nm wavelength using an extinction
coefficient calculated from the protein's amino acid sequence
(= 75 450 M
–1 cm
–1).
Biacore SPR binding analysis
Biotin-tagged H-2D
b-peptide complexes were made by in vitro
refolding with synthetic peptide as described previously [29],
except that in vitro biotinylation was not performed and
complexes were immobilised by the natural level of specific
biotinylation which occurs during expression of proteins
containing a BirA recognition sequence at their C termini
[30]. A Biacore 3000 machine was run at 25
C and 5 lL/min
flowrate.Atleast2000 RUofstreptavidinwas immobilised,by
amine coupling, to each flow cell on a CM-5 chip.
Approximately 1000 RU H-2D
b-peptide complex was immo-
bilised on each flow cell. Soluble P14 TCR was diluted to the
concentrations indicated and injected over the chip surface
using the appropriate injection program. TCR dissociated
rapidly from the H-2D
b-peptide-coated chip surface at the end
of each injection, so that no regeneration phase was required.
Binding response measurements were corrected for non-
specific control chip responses used to determine equilibrium
and kinetic binding parameters, using Biacore Biaevaluation
software.Equilibriumbindingconstants(KD)weredetermined
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fitting to the 1 : 1 Langmuir binding equation: R = Rmax
 [TCR]/(KD + [TCR]), and confirmed by linear Scatchard
analysis.
Kineticanalyseswereperformedataflowrateof50 lL/min
and at a data collection rate of 5 Hz. Data were analysed using
the Biacore Biaevaluation software and were plotted using the
Origin 6.0 program (Microcal). DG values were calculated
from KD values using the equation DG
 = –lnRT.KD and were
plotted against temperature using the Microcal
Origin 6.0 program. Least-squares fitting was performed
using the equation ~G

T = ~H
 + ~CP(T – T0)– T~S

– T~CPln(T/T0) [8].
Acknowledgements: We would like to thank Prof.
Pircher for the generous gift of P14 TCR cDNA, Andrew
Thomas for help with TCR preparation, Dr. Emma Jones
forpreparationofH-2D
b-gp33andH-2D
b-HY complexes
and Prof. Paul Morgan and Dr. Bent Jakobsen for
critically reading the manuscript. We would also like
to thank David Cole for allowing reference to unpub-
lished data. A.G. is funded by a Senior Fellowship
awarded by the MRC (G117/488), J.B. is funded by an
RCUK academic fellowship.
References
1 Rudolph,M.G.,Luz,J.G.andWilson,I.A.,Structuralandthermodynamic
correlates of T cell signaling. Annu. Rev. Biophys. Biomol. Struct. 2002. 31:
121–149.
2 Palmer, E., Negative selection – clearing out the bad apples from the T-cell
repertoire. Nat. Rev. Immunol. 2003. 3: 383–391.
3 Jameson, S. C., T cell homeostasis: Keeping useful T cells alive and live
T cells useful. Semin. Immunol. 2005. 17: 231–237.
4 Bachmann, M. F., Oxenius, A., Speiser, D. E., Mariathasan, S.,
Hengartner, H., Zinkernagel, R. M. and Ohashi, P. S., Peptide-induced
T cell receptor down-regulation on naive T cells predicts agonist/partial
agonist properties and strictly correlates with T cell activation. Eur. J.
Immunol. 1997. 27: 2195–2203.
5 Kalergis, A. M., Boucheron, N., Doucey, M. A., Palmieri, E., Goyarts, E.
C., Vegh, Z., Luescher, I. F. and Nathenson, S. G., Efficient Tcell activation
requires an optimal dwell-time of interaction between the TCR and the
pMHC complex. Nat. Immunol. 2001. 2: 229–234.
6 van der Merwe, P. A., The TCR triggering puzzle. Immunity 2001. 14:
665–668.
7 Valitutti, S., Muller, S., Cella, M., Padovan, E. and Lanzavecchia, A.,
Serial triggering of many T-cell receptors by a few peptide-MHC complexes.
Nature 1995. 375: 148–151.
8 Krogsgaard,M.,Prado, N.,Adams, E.J., He, X.L.,Chow,D. C.,Wilson, D.
B., Garcia, K. C. and Davis, M. M., Evidence that structural rearrangements
and/or flexibilityduringTCRbindingcancontributetoTcellactivation.Mol.
Cell 2003. 12: 1367–1378.
9 Holmberg, K., Mariathasan, S., Ohteki, T., Ohashi, P. S. and Gascoigne,
N. R., TCR binding kinetics measured with MHC class I tetramers reveal a
positive selecting peptide with relatively high affinity for TCR. J. Immunol.
2003. 171: 2427–2434.
10 Weidt, G., Deppert, W., Utermohlen, O., Heukeshoven, J. and Lehmann-
Grube, F., Emergence of virus escape mutants after immunization with
epitope vaccine. J. Virol. 1995. 69: 7147–7151.
11 Gronski, M. A., Boulter, J. M., Moskophidis, D., Nguyen, L. T., Holmberg,
K., Elford, A. R., Deenick, E. K. et al., TCR affinity and negative regulation
limit autoimmunity. Nat. Med. 2004. 10: 1234–1239.
12 Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-
Faienza, K., Odermatt, B., Hanahan, D. et al., Self antigens expressed by
solid tumors do not efficiently stimulate naive or activated T cells:
Implications for immunotherapy. J. Exp. Med. 1997. 186: 645–653.
13 Saibil,S.D.,Ohteki,T.,White,F.M.,Luscher,M.,Zakarian,A.,Elford,A.,
Shabanowitz, J. et al., Weak agonist self-peptides promote selection and
tuning of virus-specific T cells. Eur. J. Immunol. 2003. 33: 685–696.
14 Sebzda, E., Kundig, T. M., Thomson, C. T., Aoki, K., Mak, S. Y., Mayer, J.
P., Zamborelli, T. et al., Mature T cell reactivity altered by peptide agonist
that induces positive selection. J. Exp. Med. 1996. 183: 1093–1104.
15 Boulter,J.M.,Glick, M.,Todorov,P.T.,Baston, E.,Sami, M.,Rizkallah,P.
and Jakobsen, B. K., Stable, soluble T-cell receptor molecules for
crystallization and therapeutics. Protein Eng. 2003. 16: 707–711.
16 Chen, J. L., Stewart-Jones, G., Bossi, G., Lissin, N. M., Wooldridge, L.,
Choi, E. M., Held, G. et al., Structural and kinetic basis for heightened
immunogenicity of T cell vaccines. J. Exp. Med. 2005. 201: 1243–1255.
17 Davis,M.M.,Boniface,J.J.,Reich,Z.,Lyons,D.,Hampl,J.,Arden,B.and
Chien, Y., Ligand recognition by alpha beta T cell receptors. Annu. Rev.
Immunol. 1998. 16: 523–544.
18 Tissot,A. C.,Ciatto, C.,Mittl, P.R., Grutter,M.G.andPluckthun, A.,Viral
escape at the molecular level explained by quantitative T-cell receptor/
peptide/MHC interactions and the crystal structure of a peptide/MHC
complex. J. Mol. Biol. 2000. 302: 873–885.
19 Pircher, H., Moskophidis, D., Rohrer, U., Burki, K., Hengartner, H. and
Zinkernagel, R. M., Viral escape by selection of cytotoxic T cell-resistant
virus variants in vivo. Nature 1990. 346: 629–633.
20 Willcox, B. E., Gao, G. F., Wyer, J. R., Ladbury, J. E., Bell, J. I., Jakobsen,
B. K. and van der Merwe, P. A., TCR binding to peptide-MHC stabilizes a
flexible recognition interface. Immunity 1999. 10: 357–365.
21 Ely, L. K., Beddoe, T., Clements, C. S., Matthews, J. M., Purcell, A. W.,
Kjer-Nielsen, L., McCluskey, J. and Rossjohn, J., Disparate thermo-
dynamics governing T cell receptor-MHC-I interactions implicate extrinsic
factors in guiding MHC restriction. Proc. Natl. Acad. Sci. USA 2006. 103:
6641–6646.
22 Boniface, J. J., Reich, Z., Lyons, D. S. and Davis, M. M., Thermodynamics
of T cell receptor binding to peptide-MHC: Evidence for a general
mechanism of molecular scanning. Proc. Natl. Acad. Sci. USA 1999. 96:
11446–11451.
23 van der Merwe, P. A. and Davis, S. J., Molecular interactions mediating
T cell antigen recognition. Annu. Rev. Immunol. 2003. 21: 659–684.
24 Schamel, W. W., Arechaga, I., Risueno, R. M., van Santen, H. M.,
Cabezas, P., Risco, C., Valpuesta, J. M. and Alarcon, B., Coexistence of
multivalent and monovalent TCRs explains high sensitivity and wide range
of response. J. Exp. Med. 2005. 202: 493–503.
25 Yachi, P. P., Ampudia, J., Zal, T. and Gascoigne, N. R., Altered peptide
ligands induce delayed CD8-T cell receptor interaction – a role for CD8 in
distinguishing antigen quality. Immunity 2006. 25: 203–211.
26 Schirle, M., Keilholz, W., Weber, B., Gouttefangeas, C., Dumrese, T.,
Becker, H. D., Stevanovic, S. and Rammensee, H. G., Identification of
tumor-associated MHC class I ligands by a novel T cell-independent
approach. Eur. J. Immunol. 2000. 30: 2216–2225.
27 Li, Y., Moysey, R., Molloy, P. E., Vuidepot, A. L., Mahon, T., Baston, E.,
Dunn, S. et al., Directed evolution of humanT-cell receptors with picomolar
affinities by phage display. Nat. Biotechnol. 2005. 23: 349–354.
28 Schumacher,T.N.,Heemels,M.T.,Neefjes,J.J.,Kast,W.M.,Melief,C.J.
and Ploegh,H. L., Direct binding of peptideto emptyMHC class I molecules
on intact cells and in vitro. Cell 1990. 62: 563–567.
29 Garboczi, D. N., Hung, D. T. and Wiley, D. C., HLA-A2-peptide complexes:
Refolding and crystallization of molecules expressed in Escherichia coli and
complexed with single antigenic peptides. Proc. Natl. Acad. Sci. USA 1992.
89: 3429–3433.
30 O'Callaghan, C. A., Byford, M. F., Wyer, J. R., Willcox, B. E., Jakobsen, B.
K., McMichael, A. J. and Bell, J. I., BirA enzyme: Production and
application in the study of membrane receptor-ligand interactions by site-
specific biotinylation. Anal. Biochem. 1999. 266: 9–15.
Jonathan M. Boulter et al. Eur. J. Immunol. 2007. 37: 798–806 806
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu